State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing a beneficial ownership position in Collegium Pharmaceutical Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 1,772,243 shares of Collegium Pharmaceutical Inc common stock.
  • Percent of class: The reported position represents 5.4% of the outstanding class of common stock.
  • Shared voting power: State Street holds shared voting power over 1,689,578 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared dispositive power over 1,772,243 shares, with sole dispositive power of 0.
  • Subsidiaries involved: The position is held through investment adviser subsidiaries including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.
  • Event date: The date of the event requiring the filing is listed as September 30, 2026.

State Street's Disclosed Stake in Collegium Pharmaceutical as of September 30, 2026

State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership in Collegium Pharmaceutical Inc, whose principal executive offices are listed at 100 Technology Center Dr Suite 300, Stoughton, Massachusetts, 02072. The filing was signed on November 9, 2026 by Alok Maheshwary, identified as Senior Vice President of State Street Corporation.

According to the filing, State Street's aggregate beneficial ownership stands at 1,772,243 shares of Collegium Pharmaceutical common stock (CUSIP 19459J104), representing 5.4% of the class. The reporting person classified itself as a parent holding company (Type HC). All dispositive and voting power is shared rather than sole: the filing reports 0 shares under sole voting power, 1,689,578 shares under shared voting power, 0 shares under sole dispositive power, and 1,772,243 shares under shared dispositive power.

The filing identifies five investment adviser subsidiaries through which the position is held: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing certifies, in the words of the document, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 5.4% beneficial ownership position of 1,772,243 shares of Collegium Pharmaceutical Inc common stock as of September 30, 2026, held through five investment adviser subsidiaries with all power shared rather than sole.